Sign in

Covid-19: 3 Indian companies start supply of life-saving Remdesivir to Nepal

Remdesivir has been proved to be efficient for patients who have been put in the Intensive Care Unit and take them out of danger zone but wasn’t available in the Himalayan nation.

Updated on: Aug 21, 2020, 17:12:54 IST
Share
Share via
  • facebook
  • twitter
  • linkedin
Copy link
  • copy link

Three Indian pharmaceutical companies have started supplying Nepal with life-saving anti-viral Remdesivir to be used for the treatment of Covid-19 patients.

More than half of 123 companies permitted to import medicines from other nations are Indian companies who work on various forms for parent companies headquartered in Europe or America (Reuters)
More than half of 123 companies permitted to import medicines from other nations are Indian companies who work on various forms for parent companies headquartered in Europe or America (Reuters)

“We have confirmed three companies for supply of Remdesivir. Mylan, Cipla, and Hetero Drugs will be supplying the drugs as per our demands. We will be permitting the use of anti-viral supplied on by these companies only,” Narayan Prasad Dhakal, the Director-General of Department of Drug Administration confirmed.

“Among them, Mylan has started supplying the anti-viral to Nepal. At first, we have ordered 570 vials of it and has been delivered. Indian companies are easy to reach and the cost also comes low so we confirmed them,” he added.

Click here for full Covid-19 coverage

Remdesivir has been proved to be efficient for patients who have been put in the Intensive Care Unit and take them out of danger zone but wasn’t available in the Himalayan nation.

“It would cost around 7,800 Nepali rupees per vial when it comes to the Nepali market. It would save extra expenses of the family,” DG Dhakal said.

Nepal’s Medical Council’s directive (Interim Clinical Guidance for Covid-19) also has enlisted Remdesivir drug for the primary medication. Family of the patients who were in critical condition had to bring it from India under special arrangements but with availability on the local market, it will save on their expenses.

As per the Director-General of the Department of Drug Administration of the Himalayan nation, it is always the Indian companies who race forward to export drugs and pharmaceuticals to the nation.

More than half of 123 companies permitted to import medicines from other nations are Indian companies who work on various forms for parent companies headquartered in Europe or America.

  • HT News Desk
    ABOUT THE AUTHOR
    HT News Desk

    Follow the latest breaking news, major developments and agenda-setting stories from India and around the world with the newsdesk at Hindustan Times. Operating round the clock, the desk brings together experienced editors, reporters and correspondents to deliver fast, accurate and contextual reporting across subjects that influence public policy, governance, business, society and international affairs. The HT News Desk covers politics, elections, government policies, the economy, business and markets, science and technology, the environment, law and order, infrastructure, education, climate issues and geopolitics, while closely tracking developments across states, institutions and global capitals. The team also leads coverage of major breaking news events, policy announcements, court proceedings, natural disasters, public emergencies and significant international developments. Reports published by the newsdesk are based on information gathered from reporters on the ground, official statements, government agencies, court records, regulatory filings, recognised institutions and other authoritative sources. Stories undergo editorial scrutiny and verification processes to ensure accuracy, fairness and relevance, and are updated as events evolve and additional information becomes available. Whether covering a key political decision in New Delhi, an economic policy shift affecting millions, a landmark court ruling or a major global event, the HT News Desk aims to provide readers with reliable, fact-based journalism that delivers not only the latest developments but also the context and analysis needed to understand their wider implications.Read More